Medical/Pharmaceuticals
Encore Medical Education announces publication of the Official Best of SABCS® News Highlights summarizing key trial results from the 2022 SABCS®
Best of SABCS® News Highlights coverage will provide daily expert video
summaries along with original presentation slides of the most significant
breast cancer trials for oncologists worldwide.
SAN ANTONIO, Dec. 1, 2022 /PRNewswire/ -- Encore Medical Education,
2022-12-01 15:15
3087
SK Biopharmaceuticals Names Donghoon Lee, Head of Bio Investment Center of SK Inc., as New CEO
Mr. Lee brings expertise in global new biz development to further strengthen SK Biopharmaceuticals as SK Group's key bio business PANGYO, South Korea, Nov. 30, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that it has named Mr. Donghoon Lee, Ex...
2022-12-01 09:30
2848
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
DUBLIN, Dec. 1, 2022 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to
announce a new license agreement withCosmo Bio. This is a non-exclusive license
agreement grantingJapan's Cosmo Bio access to the ERS CRISPR/Cas9 patent
portfolio.
2022-12-01 08:00
2315
LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development
- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday,30th November 2022,...
2022-12-01 03:45
2524
Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant's PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting
* Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors * Elacestrant side effects were manageable and consistent with previously reported result...
2022-12-01 00:56
3016
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
LONDON and HONG KONG, Nov. 30, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and that it has been included as a c...
2022-11-30 22:15
4322
Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne
--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end ofFebruary 2023 -- Clinical efficacy observed in patients who have completed 12-week treatment of ASC40 or placebo was comparable t...
2022-11-30 20:39
2367
Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
CAMBRIDGE, Mass., Nov. 30, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that the first cohort has been dosed in a Phase 2 trial evaluating KP104 for the treatment of pa...
2022-11-30 20:00
2888
Cardiac Troponin Diagnostics Market Growth Boosted by High-sensitivity Point-of-care Testing
The rise in emergency department visits due to cardiac complaints drives the demand for cTn biomarkers SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- The global demand for cardiac troponin (cTn) diagnostics biomarkers is increasing as more patients with cardiac complaints are visiting emergency depa...
2022-11-30 16:12
1909
Global alliance of heart patient organizations unveils new Global Cholesterol Action Plan to prioritize unhealthy cholesterol as a main public health issue
GALWAY, Ireland, Nov. 30, 2022 /PRNewswire/ -- The Global Heart Hub has today
launched its Global Cholesterol Action Plan
2022-11-30 16:00
3067
WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan
SHANGHAI, Nov. 29, 2022 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced that it is a r...
2022-11-30 08:00
3274
First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US
SHANGHAI, Nov. 30, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient was dosed in NCT05468489, a bridging head-to-head trial inthe United States comparing HANSIZHUANG (serplulimab), an innovative anti-PD-1 monoclonal antibody (mAb) independently develo...
2022-11-30 08:00
4496
Digital Technologies Driving Transformational Growth Across the Biomanufacturing Value Chain
Digitalization enables a sustainable, effective, cost-efficient, and error-free system for biomanufacturing SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- The biomanufacturing sector is experiencing a digitalization transformation that is aligned with Industry 4.0. According to Frost & Sullivan's re...
2022-11-30 02:15
3789
United Imaging Selected to Academy of Radiology & Biomedical Imaging Research's Council of Distinguished Investigators' Class of 2022
United Imaging's Chief Technology Officer recognized at a ceremony and reception during RSNA onTuesday, November 29, 2022. HOUSTON, Nov. 29, 2022 /PRNewswire/ -- United Imaging, a global leader in producing advanced medical imaging and radiotherapy equipment, is welcomed today to the Distinguis...
2022-11-29 22:00
3430
Etiometry Applauded by Frost & Sullivan for Enabling Timely Decision Support for Critical Care with Its Digital and Automated Solution
The Etiometry Platform elevates clinical staff performance and identifies areas requiring urgent attention for better clinical outcomes, shorter hospital stays, and enhanced revenue opportunities. SAN ANTONIO, Nov. 29, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the US clinical decis...
2022-11-29 21:00
3191
A bispecific antibody molecule jointly developed by Buchang Pharmaceutical and REMD Biotherapeutics, partners of GenScript ProBio, received IND clearance from NMPA for clinical trial
NANJING, China, Nov. 29, 2022 /PRNewswire/ -- Buchang Biopharmaceutical and REMD Biotherapeutics, partners of GenScript ProBio, recently received IND approval of BC008-1A from China NMPA for Phase 1 clinical trial. BC008-1A (NMPAIND number: CXSL2200315), a bispecific antibody drug co-targeting th...
2022-11-29 21:00
3575
TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in Germany
PARIS, Nov. 29, 2022 /PRNewswire/ -- TargEDys and SymbioPharm signed an exclusive marketing and distribution agreement for the launch of SymbioLife® Satylia® inGermany. The novel dietary supplement based on the next-generation probioticHafnia alvei HA4597 will be available from January 2023. Sym...
2022-11-29 18:15
3885
Yuyu Pharma Plans to Enter the U.S. and European Markets for Hair Loss Treatment
SEOUL, South Korea, Nov. 29, 2022 /PRNewswire/ -- At the World Congress for
Hair Research 2022 (Melbourne, Australia), Yuyu Pharma shared its plans to
conduct clinical trials in the U.S. andEurope for its Dutasteride Tablet
("DUT") for the treatment of Androgenetic Alopecia ("AGA").
2022-11-29 16:20
5296
Probiotic strain SNZ 1969® helps manage IBS-D & IBS-C symptoms effectively, latest clinical study shows
HYDERABAD, India, Nov. 29, 2022 /PRNewswire/ -- Latest study shows Sanzyme Biologics'sBacillus coagulans SNZ 1969® (Weizmannia coagulans SNZ 1969), a natural spore forming probiotic strain over five decades of use and more than 30 human studies across age groups found to be effective in managing ...
2022-11-29 15:44
4607
AROA BIOSURGERY ANNOUNCES HALF YEAR RESULTS
AUCKLAND, New Zealand, Nov. 29, 2022 /PRNewswire/ -- Today New Zealand based soft-tissue regeneration company Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23. With fewer COVID-19 related disruptions, the Company has entered FY23 with momentum and delivere...
2022-11-29 13:24
5061
Week's Top Stories
Most Reposted
OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1141 media titles]
2026-11-05 06:52Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1141 media titles]
2026-11-09 21:00Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1121 media titles]
2026-11-06 22:06
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
[Picked up by 1105 media titles]
2026-11-09 23:00
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1083 media titles]
2026-11-03 22:00Most Read
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
26162
ZD Energy Unveils Overseas Smart Energy Solutions in Thailand, Leveraging Local Manufacturing and Scenario-Based Capabilities to Support the Country's Energy Transition
2026-11-06 22:12
15075
SILVERSEA MARKS HISTORIC OPENING OF THE CORMORANT AT 55 SOUTH, THE SOUTHERNMOST HOTEL ON EARTH, OFFERING A NEW GATEWAY TO ANTARCTICA
2026-11-07 01:05
14557
OceanaGold Reports Third Quarter 2026 Results
2026-11-05 06:52
14412